Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26041581 | 1.00 | KRAS (0.40) | KRASHDAC6USP30TP53FPR2 | |
| SCHEMBL23512813 | 1.00 | KRAS (0.40) | KRASHDAC6USP30TP53FPR2 | |
| SCHEMBL23513061 | 0.91 | USP30 (0.42) | HDAC6USP30TP53FPR2GPR119 | |
| SCHEMBL23512532 | 0.91 | USP30 (0.42) | HDAC6USP30TP53FPR2GPR119 | |
| SCHEMBL24558315 | 0.91 | KRAS (0.40) | KRASHDAC6USP30TP53FPR2 | |
| SCHEMBL29693256 | 0.91 | KRAS (0.41) | KRASHDAC6USP30TP53FPR2 | |
| SCHEMBL24558112 | 0.91 | KRAS (0.41) | KRASHDAC6USP30TP53FPR2 | |
| SCHEMBL24558102 | 0.89 | KRAS (0.41) | KRASHDAC6USP30TP53FPR2 | |
| SCHEMBL23512988 | 0.89 | KRAS (0.40) | KRASHDAC6USP30TP53GPR119 | |
| SCHEMBL23512593 | 0.89 | KRAS (0.40) | KRASHDAC6USP30TP53GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | KRAS 89/4885HDAC6 797/4885USP30 4265/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | KRAS 89/4885HDAC6 797/4885USP30 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.